NCT04094610 2025-11-19
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
Turning Point Therapeutics, Inc.
Bristol-Myers Squibb
AbbVie
Shenzhen BinDeBio Ltd.